Labs / CDMO: development & manufacturing

Molecular Partners
Zurich, Switzerland · molecularpartners.com
On your own
Free. Their own form.
Through Midgard
Midgard sends your request to the lab and keeps the order's messages, papers and payments in one place. Free to ask. 1% platform fee if you keep the order on Midgard.
Molecular Partners develops DARPin therapeutics for people with cancer and other serious diseases. The company is based in Zurich-Schlieren, Switzerland, with a U.S. office in Cambridge, Massachusetts, and also lists a secondary address in Concord, Massachusetts.
They take quote requests by email.
What they offer
DARPin therapeutics discovery and development
Develops custom-built DARPin drugs using in-house design and development expertise with world-class partners.
Radio-DARPin therapy development
Creates radiopharmaceutical DARPin programs for targeted radiotherapy, including programs against DLL3 and MSLN.
Switch-DARPin development
Develops logic-gated immune cell engagers for targeted and conditional immune activation.
Multispecific immuno-oncology program development
Develops multispecific therapeutics such as FAP x CD40 agonists for tumor-localized immune activation.
What they work on
- Modalities
- Antibody, Bispecific
- Therapeutic areas
- cancer, serious diseases, ovarian cancer, small cell lung cancer
- Sites
- Zurich-Schlieren, Switzerland · Cambridge, Massachusetts, United States
- Address
- 245 Main Street Cambridge, MA 02142
- Founded
- 2022
Public records
- Ownership
- Molecular Partners AG · CH GLEIF
Similar labs. 3C Therapeutics, Accellix, Adragos Pharma, AGC Biologics
Found in a contract services directory. Listing built from molecularpartners.com. Work here? Claim this listing.